Cargando…

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon

Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become availabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Douglas F., Tobias, Hillel, Min, Albert D., Rajendra, Arathi, Zic, Ivanka, Brettholz, Edward, Clain, David J., Klion, Franklin, Bernstein, David, Bodenheimer, Henry C.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003973/
https://www.ncbi.nlm.nih.gov/pubmed/21188197
http://dx.doi.org/10.1155/2010/537827
_version_ 1782193932923305984
author Meyer, Douglas F.
Tobias, Hillel
Min, Albert D.
Rajendra, Arathi
Zic, Ivanka
Brettholz, Edward
Clain, David J.
Klion, Franklin
Bernstein, David
Bodenheimer, Henry C.
author_facet Meyer, Douglas F.
Tobias, Hillel
Min, Albert D.
Rajendra, Arathi
Zic, Ivanka
Brettholz, Edward
Clain, David J.
Klion, Franklin
Bernstein, David
Bodenheimer, Henry C.
author_sort Meyer, Douglas F.
collection PubMed
description Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical efficacy with superior invitro antiviral activity, but the maximum tolerated dose is not defined. Methods. We assessed the efficacy of daily high-dose (24 ug) consensus interferon with weight-based (1000–1200 mg daily) ribavirin in HCV genotype 1-infected non-responder patients. Results. Six adverse events were documented in five patients, and the trial was terminated with no subject achieving viral clearance. Conclusions. The occurrence of serious adverse events effectively defined the upper limit of acceptable dose, while also revealing that this dose did not offer enhanced sustained viral clearance.
format Text
id pubmed-3003973
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30039732010-12-23 Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon Meyer, Douglas F. Tobias, Hillel Min, Albert D. Rajendra, Arathi Zic, Ivanka Brettholz, Edward Clain, David J. Klion, Franklin Bernstein, David Bodenheimer, Henry C. Hepat Res Treat Clinical Study Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical efficacy with superior invitro antiviral activity, but the maximum tolerated dose is not defined. Methods. We assessed the efficacy of daily high-dose (24 ug) consensus interferon with weight-based (1000–1200 mg daily) ribavirin in HCV genotype 1-infected non-responder patients. Results. Six adverse events were documented in five patients, and the trial was terminated with no subject achieving viral clearance. Conclusions. The occurrence of serious adverse events effectively defined the upper limit of acceptable dose, while also revealing that this dose did not offer enhanced sustained viral clearance. Hindawi Publishing Corporation 2010 2010-10-10 /pmc/articles/PMC3003973/ /pubmed/21188197 http://dx.doi.org/10.1155/2010/537827 Text en Copyright © 2010 Douglas F. Meyer et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Meyer, Douglas F.
Tobias, Hillel
Min, Albert D.
Rajendra, Arathi
Zic, Ivanka
Brettholz, Edward
Clain, David J.
Klion, Franklin
Bernstein, David
Bodenheimer, Henry C.
Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
title Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
title_full Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
title_fullStr Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
title_full_unstemmed Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
title_short Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
title_sort retreatment of patients nonresponsive to pegylated interferon and ribavirin with daily high-dose consensus interferon
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003973/
https://www.ncbi.nlm.nih.gov/pubmed/21188197
http://dx.doi.org/10.1155/2010/537827
work_keys_str_mv AT meyerdouglasf retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon
AT tobiashillel retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon
AT minalbertd retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon
AT rajendraarathi retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon
AT zicivanka retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon
AT brettholzedward retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon
AT claindavidj retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon
AT klionfranklin retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon
AT bernsteindavid retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon
AT bodenheimerhenryc retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon